Abstract
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
Highlights
One hundred years ago, Albert Calmette (1863–1933) and Camille Guérin (1872–1961) had almost reached their goal [1]
The data obtained were highly promising so Calmette and Guérin started the first vaccination of a human neonate born
The results of this trial revealed that of the vaccinees 5% had died and 1% of these of TB, whereas knowledge of the time held that a quarter of non-vaccinated newborns would die in the first years of life, many of them of TB [1]. This is the start of Bacille Bilié Calmette-Guérin, later shortened to Bacille Calmette–Guérin (BCG), which remains the only licensed vaccine against TB until today. This vaccine partially fulfills the goal set by Calmette and Guérin, since it protects against extrapulmonary forms of disease in infants, including life threatening TB meningitis
Summary
Albert Calmette (1863–1933) and Camille Guérin (1872–1961) had almost reached their goal [1]. In contrast to mice, do express a functional CD1 type 1 antigen presentation system, representing the only small animal model to study these unconventional vaccine research approaches As another means of refinement, new NHP modeling tools and conditions are being established for refined infectious challenge, advanced flow cytometric analyses (including that of innate subsets), and advanced imaging of disease and host response dynamics by PET/CT imaging [46]. The identification of CoP in particular will help to develop vaccines that target and strengthen protective immunity Such correlates will facilitate the selection and prioritization of candidate TB vaccines for human efficacy testing, and will reduce the protracted time scale, size, and expenses of human efficacy trials by allowing the demonstration of vaccine immunogenicity and potential efficacy at an early stage. WorkPackage 5 links to other activities in TBVAC2020, including animal models (mice, NHPs) and human clinical vaccine trial related TB BM assays; and some of WP5 partners actively participate in these activities
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
